coin-img-ETHETH-0.86%coin-img-SOLSOL-2.44%coin-img-BTCBTC-0.73%coin-img-XRPXRP-2.32%coin-img-ZECZEC-4.32%coin-img-USDCUSDC+0.01%coin-img-SUISUI+0.93%coin-img-DOGEDOGE-3.02%coin-img-ETHETH-0.86%coin-img-SOLSOL-2.44%coin-img-BTCBTC-0.73%coin-img-XRPXRP-2.32%coin-img-ZECZEC-4.32%coin-img-USDCUSDC+0.01%coin-img-SUISUI+0.93%coin-img-DOGEDOGE-3.02%coin-img-ETHETH-0.86%coin-img-SOLSOL-2.44%coin-img-BTCBTC-0.73%coin-img-XRPXRP-2.32%coin-img-ZECZEC-4.32%coin-img-USDCUSDC+0.01%coin-img-SUISUI+0.93%coin-img-DOGEDOGE-3.02%coin-img-ETHETH-0.86%coin-img-SOLSOL-2.44%coin-img-BTCBTC-0.73%coin-img-XRPXRP-2.32%coin-img-ZECZEC-4.32%coin-img-USDCUSDC+0.01%coin-img-SUISUI+0.93%coin-img-DOGEDOGE-3.02%
user-avatar
Business Today

Dr Reddy’s shares gain 2% after exclusive India private-market deal to distribute Takeda’s QDENGA

AI Market Summary
Dr Reddy's signed an exclusive distribution and marketing agreement with Takeda for QDENGA in India's private market, following CDSCO approval and ahead of a planned 2027 rollout. The news is idiosyncratic to Dr Reddy's and highlights incremental commercial upside tied to India's dengue burden, with limited broader cross-asset implications for crypto or macro markets.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.11%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Dr Reddy’s Laboratories and Takeda have signed an exclusive agreement for the distribution and marketing of Takeda’s dengue vaccine QDENGA in India’s private market. The vaccine has been approved by India’s drug regulator for people aged 4-60 and had previously been cleared in 43 countries, with more than 32 million doses distributed globally. Following the announcement, Dr Reddy’s shares rose 2.09% on the day.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.